Müller Dafne, Kontermann Roland E
Institut für Zellbiologie und Immunologie, Universität Stuttgart, Allmandring 3,1 70569 Stuttgart, Germany.
Curr Opin Mol Ther. 2007 Aug;9(4):319-26.
Bispecific antibodies recognizing two different antigens present on different cells have been developed for cellular cancer therapy in which cytotoxic effector cells are recruited to tumor cells. Initial studies with bispecific antibodies have not reached satisfactory clinical endpoints, mainly due to low efficacy, Fc-mediated side effects and immunogenicity. This has resulted in a declining interest in bispecific antibodies for cancer therapy. However, growing knowledge in effector cell biology and the implementation of antibody engineering technologies has led to a revival and the development of novel or improved strategies. Various recombinant bispecific antibodies have demonstrated efficacy in vitro andin vivo, with the first recombinant antibody molecule currently in clinical trials for the treatment of B-cell malignancies.
能够识别存在于不同细胞上的两种不同抗原的双特异性抗体已被开发用于细胞癌症治疗，即招募细胞毒性效应细胞至肿瘤细胞。双特异性抗体的初步研究尚未达到令人满意的临床终点，主要原因是疗效低、Fc介导的副作用和免疫原性。这导致对用于癌症治疗的双特异性抗体的兴趣下降。然而，效应细胞生物学知识的不断增加以及抗体工程技术的应用促使了双特异性抗体的复兴和新策略或改进策略的发展。各种重组双特异性抗体已在体外和体内显示出疗效，目前首个重组抗体分子正在进行治疗B细胞恶性肿瘤的临床试验。
